The effects of advanced glycation end-products on frailty in patients with heart failure

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061043

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

none:none

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for chronic heart failure in the 2021 "JCS/JHFS Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure"; 2. The condition has been stable for more than 1 month after treatment.

Exclusion criteria

Exclusion criteria: 1. Combined with hyperthyroidism, tumor, tuberculosis and other high metabolic wasting diseases; 2. Combined with severe liver and kidney damage; 3. Combined with severe gastrointestinal diseases and eating disorders; 4. Patients with motor system disorders; 5. Those who can not cooperate with the examination; 6. Those who have recently suffered from acute infectious diseases.

Design outcomes

Primary

Measure	Time frame
frailty phenotype;	—

Countries

China

Contacts

Public ContactHui Xiong

Wuchang Hospital Affiliated to Wuhan University of Science and Technology

xh9613076@163.com+86 13871226649

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026